B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib

Figure 1

The results of the laboratory tests performed during the patient’s follow-up. (a) Molecular response analysis based on the BCR-ABL transcript level evaluation on International Scale. (b) Peripheral blood leukocyte (black line) and absolute lymphocytes (gray dots) count during the observation time when the patient remained in CCyR and MMR. (c) Blood hemoglobin (Hgb) concentration during IM treatment. A significant drop in Hgb level was noted simultaneously with the rise of absolute lymphocyte blood count.

(a)

(b)

(c)